| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441966 | European Journal of Cancer | 2015 | 9 Pages |
Abstract
The DFS benefit previously demonstrated with sequential docetaxel is no longer observed at 10Â years. However, an exploratory analysis suggested a benefit of docetaxel in patients with highly proliferative ER-positive BC.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Amir Sonnenblick, Prudence A. Francis, Hatem A. Jr., Evandro de Azambuja, Bo Nordenskjöld, Jorge Gutiérez, Emmanuel Quinaux, Mauro G. Mastropasqua, Lieveke Ameye, Michael Anderson, Ana Lluch, Michael Gnant, Aron Goldhirsch, Angelo Di Leo,